JP2013535505A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535505A5
JP2013535505A5 JP2013524232A JP2013524232A JP2013535505A5 JP 2013535505 A5 JP2013535505 A5 JP 2013535505A5 JP 2013524232 A JP2013524232 A JP 2013524232A JP 2013524232 A JP2013524232 A JP 2013524232A JP 2013535505 A5 JP2013535505 A5 JP 2013535505A5
Authority
JP
Japan
Prior art keywords
composition
histidine
item
meglumine
cation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535505A (ja
JP5921545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/047434 external-priority patent/WO2012021715A2/en
Publication of JP2013535505A publication Critical patent/JP2013535505A/ja
Publication of JP2013535505A5 publication Critical patent/JP2013535505A5/ja
Application granted granted Critical
Publication of JP5921545B2 publication Critical patent/JP5921545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524232A 2010-08-11 2011-08-11 リナクロチドの安定な製剤 Active JP5921545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37280410P 2010-08-11 2010-08-11
US61/372,804 2010-08-11
PCT/US2011/047434 WO2012021715A2 (en) 2010-08-11 2011-08-11 Stable formulations of linaclotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016007036A Division JP2016065105A (ja) 2010-08-11 2016-01-18 リナクロチドの安定な製剤

Publications (3)

Publication Number Publication Date
JP2013535505A JP2013535505A (ja) 2013-09-12
JP2013535505A5 true JP2013535505A5 (https=) 2014-09-25
JP5921545B2 JP5921545B2 (ja) 2016-05-24

Family

ID=44630493

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013524232A Active JP5921545B2 (ja) 2010-08-11 2011-08-11 リナクロチドの安定な製剤
JP2016007036A Withdrawn JP2016065105A (ja) 2010-08-11 2016-01-18 リナクロチドの安定な製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016007036A Withdrawn JP2016065105A (ja) 2010-08-11 2016-01-18 リナクロチドの安定な製剤

Country Status (17)

Country Link
US (7) US20140005128A1 (https=)
EP (2) EP2603232B1 (https=)
JP (2) JP5921545B2 (https=)
CA (2) CA2808091C (https=)
CY (1) CY1122853T1 (https=)
DK (1) DK2603232T3 (https=)
ES (2) ES2763404T3 (https=)
HR (1) HRP20192207T1 (https=)
HU (1) HUE046922T2 (https=)
LT (1) LT2603232T (https=)
MX (1) MX348823B (https=)
PL (1) PL2603232T3 (https=)
PT (1) PT2603232T (https=)
RS (1) RS59978B1 (https=)
SI (1) SI2603232T1 (https=)
SM (1) SMT201900697T1 (https=)
WO (1) WO2012021715A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2015120471A1 (en) * 2014-02-10 2015-08-13 The Johns Hopkins University Devices for and methods of treatment of metabolic syndromes
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
JP6385299B2 (ja) * 2015-03-03 2018-09-05 株式会社日立ハイテクノロジーズ 液体クロマトグラフ用遠紫外吸光度検出装置
EP3302440B1 (en) * 2015-06-05 2021-01-06 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
MX2019007574A (es) * 2016-12-21 2019-09-04 Ironwood Pharmaceuticals Inc Metodos de tratamiento de sindrome de intestino irritable con formulaciones modificadas o de liberacion retardada de linaclotida.
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020251923A1 (en) * 2019-06-10 2020-12-17 Ironwood Pharmaceuticals, Inc. Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545931A (en) 1983-01-03 1985-10-08 Scripps Clinic And Research Foundation Synthetic heat-stable enterotoxin polypeptide of Escherichia coli
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH0223849A (ja) * 1988-06-08 1990-01-26 Morishita Pharmaceut Co Ltd ペプチド含有栄養輸液組成物
JPH03505334A (ja) 1989-04-11 1991-11-21 イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド 凍結乾燥されたペプチド製剤
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
WO1996010996A1 (en) 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
JP3009224B2 (ja) 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたdnアーゼ液体溶液
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
AU737664B2 (en) 1996-07-03 2001-08-30 Alza Corporation Non-aqueous protic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
CN1228708A (zh) 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US5705537A (en) 1997-02-24 1998-01-06 Armstrong World Industries, Inc. Phenolic foams having a low formaldehyde evolution
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
JP2002521322A (ja) 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法
MXPA01005346A (es) 1998-11-27 2003-03-27 Kanji Takada Una formulacion oral para suministro de farmaco gastrointestinal.
WO2001025266A1 (en) 1999-10-06 2001-04-12 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
JP2004501191A (ja) 2000-06-28 2004-01-15 テバ ファーマシューティカル インダストリーズ リミティド カルベジロール
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2001296389A1 (en) 2000-09-29 2002-04-08 Cognetix, Inc. Stable peptide formulations
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
CA2435835A1 (en) 2001-02-02 2002-08-15 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CA2905585C (en) 2001-03-29 2020-02-18 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
AU2002355542A1 (en) 2001-08-09 2003-02-24 Doctor's Signature Sales And Marketing International Corp. ((Dba)) Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
AU2002351755A1 (en) 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
AU2003301654A1 (en) 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
RU2329823C2 (ru) 2002-10-29 2008-07-27 Алза Корпорейшн Стабилизированные твердые полипептидные частицы
PL377479A1 (pl) 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
ATE390142T1 (de) 2003-05-14 2008-04-15 Indus Biotech Pvt Ltd Synergistische zusammensetzung zur behandlung von diabetes mellitus
EP1641486B1 (en) 2003-06-10 2012-04-18 LG Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
WO2006071102A1 (en) 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US20080279935A1 (en) 2005-02-18 2008-11-13 Swg Invest As Composition Comprising a Powder Containing Microencapsulated Polyunsaturated Long-Chain Esterified Fatty Acids Distributed in an Effervescent Base
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
WO2007022531A2 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
CN101282657A (zh) * 2005-10-28 2008-10-08 雀巢技术公司 支链氨基酸的使用方法
EP1991241A4 (en) 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
WO2007101161A2 (en) 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
BRPI0716261A2 (pt) 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
JP2010513462A (ja) 2006-12-20 2010-04-30 バイエル・ヘルスケア・エルエルシー 第VIIおよび第VIIa因子組成物
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
WO2008106429A2 (en) 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
PE20110543A1 (es) * 2008-08-15 2011-08-04 Ironwood Pharmaceuticals Inc Formulacion solida oral que comprende linaclotida, cation de calcio y leucina
WO2010027405A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
EP2331077A2 (en) 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
CA2770077A1 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
MX2012001691A (es) 2009-08-12 2012-02-29 Forest Lab Holdings Ltd Composiciones de linaclotida que se desintegran oralmente.
EP2603232B1 (en) 2010-08-11 2019-09-25 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.

Similar Documents

Publication Publication Date Title
JP2013535505A5 (https=)
JP2012521994A5 (https=)
JP2013501071A5 (https=)
JP2015519330A5 (https=)
JP2015512406A5 (https=)
JP2008533007A5 (https=)
HRP20161277T1 (hr) Pripravci za liječenje centralno posredovane mučnine i povraćanja
JP2012193216A5 (https=)
JP2016531913A5 (https=)
JP2012136541A5 (https=)
JP2009524676A5 (https=)
JP2013542261A5 (https=)
JP2014129360A5 (https=)
JP2013532729A5 (https=)
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
ME02150B (me) Derivati piperidinona kao inhibitori mdm2 za lečenje kancera
JP2010270124A5 (https=)
WO2009029622A3 (en) Antiviral drugs for treatment of arenavirus infection
JP2011502997A5 (https=)
JP2012517987A5 (ja) 吸入用の医薬組成物のfpd特性を設定する方法
JP2013503110A5 (https=)
RU2013141534A (ru) Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
JP2012523437A5 (https=)
JP2014503593A5 (https=)
JP2018090566A5 (https=)